Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672388 | 0.90 | LTA4H (0.43) | LTA4HALDH1A1 | |
| SCHEMBL5672025 | 0.86 | LTA4H (0.47) | FAAHDRD2DRD3KCNH2LTA4H | |
| SCHEMBL5669916 | 0.83 | KCNH2 (0.41) | FAAHNPY1RKCNH2LTA4HLMNA | |
| SCHEMBL5670000 | 0.81 | LTA4H (0.49) | NPY1RLTA4HLMNAALDH1A1 | |
| SCHEMBL6750843 | 0.81 | FAAH (0.45) | FAAHDRD2DRD3KCNH2LMNA | |
| SCHEMBL6750833 | 0.79 | NPY1R (0.47) | NPY1RLTA4H | |
| SCHEMBL6750846 | 0.79 | SLC6A3 (0.41) | FAAH | |
| SCHEMBL5406376 | 0.76 | MAPT (0.43) | NPY1RLTA4H | |
| SCHEMBL5397997 | 0.73 | MAPT (0.43) | — | |
| SCHEMBL5672391 | 0.70 | KDM4E (0.49) | FAAHDRD2DRD3HRH1ADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097569-A1 | Aryl substituted hydantoin compounds and their use as sodium channel blockers | EURO-CELTIQUE S.A. | 2004-05-20 | — | — | US | claimed |
| US-20040097569-A1 | Aryl substituted hydantoin compounds and their use as sodium channel blockers | EURO-CELTIQUE S.A. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097569-A1 | Aryl substituted hydantoin compounds and their use as sodium channel blockers | SCN1A, CACNA1S, SCN1B | FAAH 254/4885NPY1R 1069/4885DRD2 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.